【摘要】 肺动脉高压是一类以小肺动脉血管重构为特征的恶性肺血管疾病,肺血管阻力进行性升高最终导致右心衰竭死亡。肺动脉高压的药物治疗主要针对前列环素、内皮素、一氧化氮三个靶点。他达那非(Tadalafil)是一种口服、长效、选择性5-型磷酸二酯酶抑制剂,增加环磷酸鸟苷(cGMP)浓度,通过一氧化氮途径起到治疗作用。PHIRST临床试验证实肺动脉高压患者每日一次口服他达那非40mg,能够提高6分钟步行距离,减少临床恶化。本文就他达那非治疗肺动脉高压研究新进展作一综述。更多还原

【Abstract】 Pulmonary arterial hypertension(PAH) is a progressive pulmonary vascular disease that is characterized by small pulmonary vascular remodeling and elevation of pulmonary vascular resistance,leading right heart failure and death.Treatment options for pulmonary arterial hypertension target the prostacyclin,endothelin,or nitric oxide pathways.Tadalafil,a phosphodiesterase type-5 inhibitor,increases cGMP,the final mediator in the nitric oxide pathway.PHIRST trial concluded that tadalafil 40 mg improved 6 minutes walk distance and reduced clinical worsening in patients with pulmonary arterial hypertension.This article reviews tadalafil therapy for pulmonary arterial hypertension.更多还原